SciClone Pharmaceuticals to Present at Two November Investor Conferences

Merriman Investor Summit on Tuesday, November 10 at 3:20 pm ET; Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17 at 9:25 am ET

• Press Release
• Source: SciClone Pharmaceuticals, Inc.
• On 7:00 am EST, Tuesday November 3, 2009

FOSTER CITY, CA--(Marketwire - 11/03/09) - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN - News) today announced that it will present at two upcoming investor conferences in New York City: Merriman Investor Summit, and Lazard Capital Markets 6th Annual Healthcare Conference. Gary Titus, SciClone's Senior Vice President and Chief Financial Officer, will present a corporate overview and business update at each conference.

�
WHEN:   Merriman Investor Summit
        Tuesday, November 10; 3:20 pm ET
        New York, NY

WHEN:   Lazard Capital Markets 6th Annual Healthcare Conference
        Tuesday, November 17; 9:25 am ET
        New York, NY

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone

SciClone Pharmaceuticals (NASDAQ:SCLN - News) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in preclinical studies as an enhancer of novel H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead(TM) in China, where the product is under regulatory review. The Company also has commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm(TM) in China and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com.